1374208-43-1

Basic information

• Product Name: 7-bromo-6-fluoro-1H-quinazoline-2,4-dione
• CAS NO: 1374208-43-1
• Molecular Weight: 259.034
• Mol File: 1374208-43-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 7-bromo-6-fluoro-1H-quinazoline-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-6-fluoro-1H-quinazoline-2,4-dione(1374208-43-1)
• EPA Substance Registry System: 7-bromo-6-fluoro-1H-quinazoline-2,4-dione(1374208-43-1)

Safety Data

• Hazardous Substances Data: 1374208-43-1(Hazardous Substances Data)

Upstream product

• 1374208-42-0 3-fluoro-4-bromo-6-aminobenzoic acid 
• 57-13-6 urea 
• 1395493-30-7 2-amino-4-bromo-5-fluorobenzoic acid methyl ester 
• 1020717-99-0 4-bromo-5-fluoro-2-nitrobenzoic acid 
• 656-64-4 3-bromo-4-fluoroaniline 
• 1374208-41-9 5-fluoro-6-bromo-1H-indolin-2,3-dione 
• 1374208-40-8 N-(3-bromo-4-fluorophenyl)-2-hydroxyiminoacetamide 
• 60-35-5 acetamide 

Downstream Products

• 1374208-44-2 2,4-dichloro-6-fluoro-7-bromoquinazoline 

Relevant articles and documents

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Substituted Amino-Pyrimidine Derivatives

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.